Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Moderna and Merck revealed Thursday that their personalized mRNA vaccine targeting melanoma, the most lethal form of skin cancer, reduced the likelihood of death or recurrence by 42 percent compared to traditional treatment, according to a late-stage trial. The pharmaceutical companies are already collaborating with regulatory agencies to secure approval for the vaccine.

This victory signifies a major breakthrough in melanoma treatment, and the potential of mRNA vaccines and personalized medicines to revolutionize cancer therapies is gaining momentum. Moderna CEO Stéphane Bancel stated that the company had always believed mRNA technology could enable the creation of tailored cancer treatments for each patient's unique tumor.

The trial results mark a critical milestone in realizing this vision, demonstrating the transformative impact of rethinking medicine production. These findings further validate the belief that mRNA has the capacity to fundamentally alter cancer treatment, Bancel added.